| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/24/2005 | US20050043341 For stimulation of reverse cholesterol transport, lowering low density lipoproteins in blood; for treatment of hypolipoproteinaemia, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, arteriosclerosis adiposity and obesity stroke or Alzheimer's disease |
| 02/24/2005 | US20050043337 Selective beta3 adrenergic agonists |
| 02/24/2005 | US20050043336 Quinazoline derivatives as antitumor agents |
| 02/24/2005 | US20050043335 Heterocyclic derivatives of glycinamide and their medical use |
| 02/24/2005 | US20050043333 Quinazolinone derivative |
| 02/24/2005 | US20050043330 Antiinflammation agents |
| 02/24/2005 | US20050043328 Such as 6-(2-hydroxy-3-chloroxybenzylamino)purine, 6-(2-hydroxy-4-chlorobenzylamino)purine; agriculture; cloning; immunostimulation |
| 02/24/2005 | US20050043304 Lower alkyl molecular weight amine as enzyme inhibitors for use in the treatment of tryptase enzyme inhibitors inhibitorsfor respiratory system disorders, antiinflammatory agents, inflammatory bowel disease, hyperprolific skin disorders, vascular edema and rheumatoid arthritis |
| 02/24/2005 | US20050043303 prophylaxis of cardiovascular disorders comprising administering to mammals inhibitors of cyclic guanosine monophosphate metabolizing phosphodiesterases such as 2-{2-Ethoxy-5-[4-(2-hydroxy-ethyl)-piperazine-1-sulfonyl]-phenyl}-6-methyl-8-propyl-3H-imidazo[1,5-a][1,3,5]triazin-4-one; antiarrythmic agents |
| 02/24/2005 | US20050043302 New indole derivatives as factor Xa inhibitors |
| 02/24/2005 | US20050043299 Inhibitors of dipeptidyl peptidase iv |
| 02/24/2005 | US20050043293 Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 02/24/2005 | US20050043270 administering hyaluronic acid or a pharmaceutically acceptable salt to a human or a non-human animal to treat Crohn disease or ulcerative colitis |
| 02/24/2005 | US20050043241 Use of inhibitors of given amino acid sequence; inhibit phosphorylation of a transcription factor; can be used to treat or prevent diabetes, ionizing radiation damage, autoimmune diseases, ischemia/reperfusion injuries, heart hypertrophies, cancer |
| 02/24/2005 | US20050043226 having a building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thioester, or disulfide; used to treat cancers, diabetes, diabetic-associated complications, endocrine disorders, gastrointestinal disorders, and pancreatitis |
| 02/24/2005 | US20050042754 Induction of the formation of insulin-producing cells via gene transfer of pancreatic beta-cell-associated transcriptional factor |
| 02/24/2005 | US20050042731 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders |
| 02/24/2005 | US20050042729 Expression vector comprising nucleotide sequences conding immunoglobulin/interferon fusion for use in targeting and treatment of liver disorders |
| 02/24/2005 | US20050042653 Human transport protein homologs |
| 02/24/2005 | US20050042614 Point mutations; dipeptidyl-peptidase inhibitors; kits |
| 02/24/2005 | US20050042354 Antiradicals and fat compositions, foods, drinks, drugs or feeds containing the antiradicals |
| 02/24/2005 | US20050042317 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/24/2005 | US20050042296 Superfine aqueous dispersion of noble metal for head massage |
| 02/24/2005 | US20050042280 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 02/24/2005 | US20050042279 Pharmaceutical formulation comprising more than 15% tamoxifen |
| 02/24/2005 | US20050042237 Method for administering a spill resistant pharmaceutical system |
| 02/24/2005 | US20050042236 Plant extract active as an immunostimulating agent |
| 02/24/2005 | US20050042215 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 02/24/2005 | US20050042202 Gentamicin, amikacin, tobramycin, netilmicin, cephalosporin, ceftazidine, maxalactam, carbopenem, imipenem, aztreonam, ampicillin, penicillin, ureidopenicillin, augmentin, amphotericin, famvir and/or acyclovir; and Vpr protein, fragment or nucleic acid encoding; systemic inflammatory response syndrome |
| 02/24/2005 | US20050042201 Synergistic mixture of glycoprotein and angiogenesis inhibitor comprising angiostatin, thrombostatin, endostatin, interferon, interferon-inducible factor 10, platelet factor, and/or cyclooxygenase inhibitor; antitumor and anticarcinogenic agents |
| 02/24/2005 | US20050042172 Administration of medicaments by vaporisation |
| 02/24/2005 | US20050042171 Only once daily administration of an antispasmodic beta-2 adrenergic agonist and an antiinflammatory corticosteroid; inhalation; salmeterol xinafoate |
| 02/24/2005 | CA2577239A1 Nitrogen-containing fused ring compound and use thereof as hiv integraseinhibitor |
| 02/24/2005 | CA2535619A1 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
| 02/24/2005 | CA2535416A1 Imidazopyridine derivatives |
| 02/24/2005 | CA2533641A1 Lactoperoxidase as an osteogenesis promoter |
| 02/23/2005 | EP1508570A1 Novel physiolgically active substances |
| 02/23/2005 | EP1508566A1 (2s)-2-ethylphenylpropionic acid derivative |
| 02/23/2005 | EP1508561A1 2-(a-HYDROXYPENTYL) BENZOATE AND ITS PREPARATION AND USE |
| 02/23/2005 | EP1508340A1 Insulin resistance improving agents |
| 02/23/2005 | EP1508332A1 Medicinal composition |
| 02/23/2005 | EP1508327A1 Use of chromen-4-one derivatives for the care of skin and hair |
| 02/23/2005 | EP1507875A2 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/23/2005 | EP1507781A2 Process for preparing maytansinol |
| 02/23/2005 | EP1507780A1 Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| 02/23/2005 | EP1507779A1 Inhibitors of jak and cdk2 protein kinases |
| 02/23/2005 | EP1507778A1 Anti-tumour polycyclic carboxamides |
| 02/23/2005 | EP1507776A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| 02/23/2005 | EP1507775A1 Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| 02/23/2005 | EP1507773A1 Macrocyclic compounds useful as pharmaceuticals |
| 02/23/2005 | EP1507772A1 Methods of using thiazolidinedithione derivatives |
| 02/23/2005 | EP1507765A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 02/23/2005 | EP1507759A1 Cyanoguanidine produgs |
| 02/23/2005 | EP1507758A2 Indole derivatives and their use as ligands for cb2 receptors |
| 02/23/2005 | EP1507756A1 Ccr9 inhibitors and methods of use thereof |
| 02/23/2005 | EP1507754A1 Alkoxy aryl beta-2 adrenergic receptor agonists |
| 02/23/2005 | EP1507555A2 Induction of antigen specific immunologic tolerance |
| 02/23/2005 | EP1507554A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 02/23/2005 | EP1507544A1 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 02/23/2005 | EP1507542A2 Anti-cancer formulation |
| 02/23/2005 | EP1507537A1 Combination of an ace inhibitor, a calcium channel blocker and a diuretic |
| 02/23/2005 | EP1507533A2 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins |
| 02/23/2005 | EP1507532A2 Use of quinoline derivatives with anti-integrase effect and applications thereof |
| 02/23/2005 | EP1507529A1 Combination of organic compounds |
| 02/23/2005 | EP1507528A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting |
| 02/23/2005 | EP1507527A2 Methods for enhancing motor performance and/or endurance |
| 02/23/2005 | EP1507518A1 Combination immediate release controlled release levodopa/carbidopa dosage forms |
| 02/23/2005 | EP1507517A1 Microparticles bearing cells and active substances |
| 02/23/2005 | EP1507514A2 Controlled release compositions of estradiol metabolites |
| 02/23/2005 | EP1395583B1 New phenylpiperazines |
| 02/23/2005 | EP1317421B1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 02/23/2005 | EP1286986B1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain |
| 02/23/2005 | EP1274710B1 Novel heteroaryl-diazabicycloalkanes |
| 02/23/2005 | EP1261606B1 Substituted oxazolidinones and their use in the field of blood coagulation |
| 02/23/2005 | EP1226128B1 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds |
| 02/23/2005 | EP1177177B1 Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands |
| 02/23/2005 | EP1175224B1 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 02/23/2005 | EP1140125B1 Extracts of celery seed for the prevention and treatment of inflammation and gastrointestinal irritation |
| 02/23/2005 | EP1107962B1 Quinolin-2-one derivatives useful as anticancer agents |
| 02/23/2005 | EP1066304B1 Macrolide lhrh antagonists |
| 02/23/2005 | EP1058544B1 Inhibition of tnf activity with compositions comprising heparin and soluble tnf recpetors |
| 02/23/2005 | CN1585778A Modified anti-TNF alpha antibody |
| 02/23/2005 | CN1585777A 肝脏x受体激动剂 Liver x receptor agonist |
| 02/23/2005 | CN1585772A Chemokine receptor antagonists and methods of use thereof |
| 02/23/2005 | CN1585771A Polycyclic guanine derivative phosphodiesterase V inhibitors |
| 02/23/2005 | CN1585769A A2b adenosine receptor antagonists |
| 02/23/2005 | CN1585768A Pyrazole derivatives as psychopharmaceuticals |
| 02/23/2005 | CN1585767A Dimeric compounds and their use as anti-viral agents |
| 02/23/2005 | CN1585765A Dimeric compounds and their use as anti-viral agents |
| 02/23/2005 | CN1585763A Piperidine derivatives and their use as modulators of chemokine receptor activity especially CCR5 |
| 02/23/2005 | CN1585757A Oligopeptides and compositions containing them as cathepsin S inhibitors |
| 02/23/2005 | CN1585756A Substituted diphenyl heterocycles useful for treating HCV infection |
| 02/23/2005 | CN1585755A Benzamide and heteroarylamide as P2X7 receptor antagonists |
| 02/23/2005 | CN1585754A Quinazoline derivatives as antitumor agents |
| 02/23/2005 | CN1585752A 4, 4-difluoro-1, 2, 3, 4-tetrahydro-5H-1-benzazepine derivatives or salts thereof |
| 02/23/2005 | CN1585751A 喹啉化合物 Quinoline compound |
| 02/23/2005 | CN1585750A Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors |
| 02/23/2005 | CN1585745A Hydroxyfattysulfonic acid analogs |
| 02/23/2005 | CN1585742A Aryl aniline beta-2 adrenergic receptor agonists |
| 02/23/2005 | CN1585648A Enamel matrix protein compositions for modulating immune response |